Research Program in Men's Health: Aging and Metabolism, Division of Endocrinology and Metabolism, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Northwestern Medicine McHenry Hospital, Chicago Medical School, Rosalind Franklin University of Medicine and Science, McHenry, IllinoisUSA.
J Clin Endocrinol Metab. 2022 Feb 17;107(3):614-626. doi: 10.1210/clinem/dgab772.
Injections with intramuscular (IM) testosterone esters have been available for almost 8 decades and not only result in predictable serum testosterone levels but are also the most inexpensive modality. However, they are difficult to self-administer and associated with some discomfort. Recently, subcutaneous (SC) administration of testosterone esters has gained popularity, as self-administration is easier with this route. Available data, though limited, support the feasibility of this route. Here we review the pharmacokinetics and safety of SC testosterone therapy with both long- and ultralong-acting testosterone esters. In addition, we provide guidance for clinicians on how to counsel and manage their patients who opt for the SC route.
Systematic review of available literature on SC testosterone administration including clinical trials, case series, and case reports. We also review the pharmacology of testosterone absorption after SC administration.
Available evidence, though limited, suggests that SC testosterone therapy in doses similar to those given via IM route results in comparable pharmacokinetics and mean serum testosterone levels. With appropriate training, patients should be able to safely self-administer testosterone esters SC with relative ease and less discomfort compared with the IM route.
Although studies directly comparing the safety of SC vs IM administration of testosterone esters are desirable, clinicians should consider discussing the SC route with their patients because it is easier to self-administer and has the potential to improve patient adherence.
肌肉内(IM)睾酮酯注射已有近 80 年的历史,不仅能使血清睾酮水平可预测,而且费用最低。但是,它们难以自行注射,且会带来一些不适。最近,睾酮酯的皮下(SC)给药已经变得流行起来,因为这种途径更容易自行给药。虽然数据有限,但可用数据支持这种途径的可行性。本文我们回顾了长作用和超长效睾酮酯的 SC 睾酮治疗的药代动力学和安全性。此外,我们为选择 SC 途径的患者的临床医生提供了关于咨询和管理的指导。
对 SC 睾酮给药的现有文献进行系统评价,包括临床试验、病例系列和病例报告。我们还回顾了 SC 给药后睾酮吸收的药理学。
尽管证据有限,但可用的证据表明,以与 IM 途径相似的剂量给予的 SC 睾酮治疗会产生相似的药代动力学和平均血清睾酮水平。经过适当的培训,患者应该能够安全地自行 SC 给予睾酮酯,与 IM 途径相比,相对容易且不适感更少。
尽管理想情况下需要直接比较 SC 与 IM 给予睾酮酯的安全性的研究,但临床医生应该考虑与患者讨论 SC 途径,因为它更容易自行给药,并有可能提高患者的依从性。